Patents by Inventor Hiroshi Nagase
Hiroshi Nagase has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12275330Abstract: A vehicle includes a battery including an all-solid-state battery configured to be externally chargeable with electric power supplied from outside of the vehicle, a heater configured to heat the battery, and a control device configured to control the heater. The control device controls the heater such that when a predetermined condition related to the external charging is satisfied, the temperature of the battery during execution of the external charging is higher than when the predetermined condition is not satisfied. The predetermined condition includes a condition that an elevation of the vehicle during the execution of the external charging is higher than a predetermined height.Type: GrantFiled: September 14, 2023Date of Patent: April 15, 2025Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Tsubasa Migita, Hiroshi Nagase, Yoichi Ogura, Daisuke Mukai
-
Publication number: 20240380233Abstract: The ECU performs a step of determining whether charging/discharging control is being executed, a step of acquiring the temperature of the terminal portion when it is determined that charging/discharging control is being executed, and a step of determining the charging power limit value, a step of setting a discharge power limit value, and a step of performing charge/discharge control using the set charge power limit value and the set discharge power limit value.Type: ApplicationFiled: January 22, 2024Publication date: November 14, 2024Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Hideki HAGIWARA, Hiroshi Nagase, Yasumasa Oguma, Jun Yoshida, Tsubasa Migita, Yoshihiro Uchida
-
Patent number: 12109209Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid ? receptor agonist activity.Type: GrantFiled: December 15, 2022Date of Patent: October 8, 2024Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Publication number: 20240266630Abstract: A battery system includes: a battery case; a battery housed in the battery case, the battery being composed of a sulfide-based all-solid-state battery; a first detection unit located on a bottom surface of the battery case inside the battery case and configured to detect hydrogen sulfide; a second detection unit located vertically above the bottom surface inside the battery case and configured to detect hydrogen sulfide; and a control device. The control device includes an abnormality processing unit configured to perform an abnormality process based on detection results from the first detection unit and the second detection unit. The abnormality processing unit is configured to perform a first abnormality process when hydrogen sulfide is detected only by the first detection unit, and to perform a second abnormality process when hydrogen sulfide is detected by the second detection unit.Type: ApplicationFiled: January 5, 2024Publication date: August 8, 2024Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Hideki Hagiwara, Hiroshi Nagase, Yasumasa Oguma, Jun Yoshida, Tsubasa Migita, Yoshihiro Uchida
-
Patent number: 11673867Abstract: The present invention aims to provide a novel low-molecular-weight compound showing an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.Type: GrantFiled: December 11, 2018Date of Patent: June 13, 2023Assignees: University of Tsukuba, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Hiroshi Nagase, Tsuyoshi Saitoh, Masashi Yanagisawa, Yoko Irukayama
-
Patent number: 11643411Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: GrantFiled: October 13, 2020Date of Patent: May 9, 2023Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Patent number: 11633392Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor-related diseases (for example, headache) can be treated or prevented.Type: GrantFiled: September 15, 2017Date of Patent: April 25, 2023Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Patent number: 11011745Abstract: To provide an anode mixture configured to, when used in an all-solid-state battery, decrease the resistance of the all-solid-state battery and increase the charging performance of the all-solid-state battery, wherein the anode mixture is an anode mixture for an all-solid-state battery comprising an anode comprising an anode mixture layer; wherein the anode mixture contains a first anode active material and a second anode active material; and wherein a difference between a reaction potential of the first anode active material with respect to lithium metal and a reaction potential of the second anode active material with respect to lithium metal, is 1.0 V or more.Type: GrantFiled: September 19, 2019Date of Patent: May 18, 2021Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventor: Hiroshi Nagase
-
Patent number: 10995092Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: GrantFiled: July 19, 2019Date of Patent: May 4, 2021Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Eriko Nakata, Masaaki Hirose, Isao Ooi
-
Patent number: 10916808Abstract: One aspect of the present invention provides a sulfide solid-state battery provided with: a negative electrode collector containing copper; a negative electrode mix layer disposed on the negative electrode collector, and containing a negative electrode active material; a positive electrode mix layer containing a positive electrode active material; a sulfide solid electrolyte layer sandwiched between the negative electrode mix layer and the positive electrode mix layer, and having a protruding portion that protrudes from a peripheral edge of the negative electrode mix layer and extends up to the negative electrode collector; and a reference electrode disposed in the protruding portion.Type: GrantFiled: April 26, 2019Date of Patent: February 9, 2021Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventor: Hiroshi Nagase
-
Patent number: 10525015Abstract: The present invention relates to a nalfurafine-containing percutaneous absorption patch having a support, a drug layer and a control layer which are laminated successively, wherein the drug layer contains at least one kind of a drug selected from the group consisting of nalfurafine and a salt thereof, and capable of maintaining a given level of drug skin permeation amount without permeation of an excess amount of the drug through the skin in a short time even when applied to the skin in which the horny cell layer and the like are damaged and the skin barrier is insufficient.Type: GrantFiled: June 24, 2016Date of Patent: January 7, 2020Assignee: UNIVERSITY OF TSUKUBAInventors: Hiroshi Nagase, Makiko Tada, Megumi Yashima, Takeshi Saiki
-
Patent number: 10442802Abstract: A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(?O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.Type: GrantFiled: March 17, 2016Date of Patent: October 15, 2019Assignee: NIPPON CHEMIPHAR CO., LTD.Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
-
Patent number: 10396346Abstract: A method of manufacturing a negative electrode for a nonaqueous electrolyte secondary battery, the method includes mixing negative electrode active material particles and ferroelectric particles with each other to form first composite particles in which the ferroelectric particles are attached to the negative electrode active material particles; mixing the first composite particles and a binder with each other to form granulated particles; applying pressure to an aggregate of the granulated particles to form a sheet-shaped negative electrode mixture layer; and arranging the negative electrode mixture layer on a main surface of a negative electrode current collector foil.Type: GrantFiled: February 10, 2016Date of Patent: August 27, 2019Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Koji Kinoshita, Hiroshi Nagase, Tatsuya Hashimoto
-
Patent number: 10377763Abstract: The purpose of the present invention is to provide a compound useful as a prophylactic or therapeutic agent for various diseases and symptoms related to orexin receptors, and a medical usage of the same. The present invention provides a morphinan derivative represented by the general formula (I) below or a pharmaceutically acceptable acid addition salt thereof, the morphinan derivative having excellent selectivity for and antagonism against orexin receptors and excellent therapeutic and prophylactic effects on drug dependence, and an orexin receptor antagonist and a therapeutic or prophylactic agent for drug dependence each containing it as an active ingredient.Type: GrantFiled: October 28, 2016Date of Patent: August 13, 2019Assignee: UNIVERSITY OF TSUKUBAInventors: Hiroshi Nagase, Naoshi Yamamoto, Yoko Irukayama, Tsuyoshi Saitoh, Masashi Yanagisawa, Yasuyuki Nagumo
-
Patent number: 10361424Abstract: A method of manufacturing a negative electrode for a nonaqueous electrolyte secondary battery, the method includes mixing negative electrode active material particles and ferroelectric particles with each other to form first composite particles in which the ferroelectric particles are attached to the negative electrode active material particles; mixing the first composite particles and a binder with each other to form granulated particles; applying pressure to an aggregate of the granulated particles to form a sheet-shaped negative electrode mixture layer; and arranging the negative electrode mixture layer on a main surface of a negative electrode current collector foil.Type: GrantFiled: February 10, 2016Date of Patent: July 23, 2019Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Koji Kinoshita, Hiroshi Nagase, Tatsuya Hashimoto
-
Patent number: 10351522Abstract: The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.Type: GrantFiled: June 10, 2016Date of Patent: July 16, 2019Assignees: UNIVERSITY OF TSUKUBA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Hiroshi Nagase, Masashi Yanagisawa, Tsuyoshi Saitoh, Noriki Kutsumura, Yoko Irukayama
-
Patent number: 10141602Abstract: A problem of the present invention is to provide a lithium solid battery in which generation of short-circuits caused by dendrite is inhibited. The present invention solves the problem by providing a lithium solid battery comprising a solid electrolyte layer having a sulfide glass containing an ion conductor which has a Li element, a P element and a S element, and having an average pore radius calculated by mercury press-in method being 0.0057 ?m or less.Type: GrantFiled: December 11, 2014Date of Patent: November 27, 2018Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Takamasa Ohtomo, Hisatsugu Yamasaki, Hiroshi Nagase
-
Patent number: 9963460Abstract: A morphinan derivative represented by the following formula (I), a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a medicament, an analgesic and an antipruritic drug including the same as an active ingredient: wherein R is selected from hydrogen and C1-6 alkyl, and n represents an integer of 0 to 2.Type: GrantFiled: March 20, 2017Date of Patent: May 8, 2018Assignees: University of Tsukuba, Nippon Chemiphar Co., Ltd.Inventors: Hiroshi Nagase, Naoshi Yamamoto
-
Patent number: 9853509Abstract: Torque is improved in a composite torque rotating electric machine that uses permanent magnets having a low residual magnetic flux density such as ferrite magnets, and includes: a stator comprising armature windings arranged at a fixed interval at multiple positions on the inner periphery; a rotor which has a permanent magnet in a cylindrical core comprising laminated magnetic steel sheets and is arranged inside of the stator; and magnetic flux blocking units provided across the circumferential direction on the outer periphery of the rotor that block the closed loop magnetic flux generated around the stator windings. The magnetic flux blocking units can be multiple permanent magnets, with a non-magnetic body such as an air gap disposed between them. The distance between the permanent magnets and the non-magnetic part can be smaller than the interval at which the armature windings are arranged.Type: GrantFiled: May 28, 2012Date of Patent: December 26, 2017Assignee: AIDA ENGINEERING, LTD.Inventors: Yukinari Fujisawa, Masataka Yahara, Hiroshi Nagase, Fumio Tajima, Yoshihiro Yamaguchi
-
Patent number: 9815787Abstract: The present invention aims to provide a novel low-molecular-weight compound having an orexin agonist activity, which is expected to be useful as a superior agent for the treatment or prophylaxis of narcolepsy. The present invention provides a compound showing superior orexin agonist activity which is represented by the formula (I) wherein each symbol is as defined in the DESCRIPTION, and a pharmaceutically acceptable acid addition salt thereof, as well as an orexin agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.Type: GrantFiled: December 12, 2014Date of Patent: November 14, 2017Assignee: University of TsukubaInventors: Hiroshi Nagase, Takashi Nagahara